上皮性卵巢肿瘤中EZH2和PTEN蛋白的表达及意义
|
摘要
目的：研究EZH2和PTEN蛋白在上皮性卵巢肿瘤组织中的表达,并探讨两种蛋白与上皮性卵巢癌临床病理特征的关系及它们之间的相关性。
方法：选用(陕西)超英生物科技公司的卵巢肿瘤组织芯片(OV1005),包括正常卵巢组织20例、上皮性良性卵巢肿瘤18例、上皮性交界性卵巢肿瘤7例、上皮性卵巢癌55例。采用免疫组化方法检测EZH2和PTEN蛋白在卵巢肿瘤组织芯片中的表达。采用X2检验和Fisher确切概率法分析EZH2和PTEN蛋白在各卵巢肿瘤组织中的表达及与临床病理因素之间的关系；用Spearman等级相关分析两种蛋白的相关性。
结果：1.EZH2蛋白在正常卵巢组织、良性卵巢肿瘤、交界性卵巢肿瘤及卵巢癌组织中的表达率分别为5%、33.3%、42.9%、67.3%,四组间差别有统计学意义(P<0.05)。在卵巢癌组织中, EZH2在Ⅰ-Ⅱ期中的表达(56.7%)低于Ⅲ-Ⅳ期中的表达(88.9%),在无淋巴结无转移组中的表达(56.8%)低于有转移组中的表达(100%),两组间差别均有统计学意义(P<0.05)；随病理分级的升高,EZH2蛋白表达水平也增高,G1、G2、G3中EZH2阳性表达率分别为：42.9%、78.3%、90.9%,三组间差别有统计学意义(P<0.05)；EZH2蛋白的表达水平在不同的年龄、病理类型中差异无显著性(P>0.05)；
2.PTEN在正常卵巢组织、良性卵巢肿瘤、交界性卵巢肿瘤及卵巢癌组织中的表达率分别为100%、66.7%、42.9%、38.2%,四组间差别有统计学意义(P<0.05)。在卵巢癌组织中,PTEN在Ⅰ-Ⅱ期中的表达(51.4%)高于Ⅲ-Ⅳ期中的表达(11.1%),在无淋巴结转移组中的表达(51.4%)高于有淋巴结转移组中的表达(0%),两组间差别均有统计学意义(P<0.05)；随病理分级的升高,PTEN表达水平降低,G1、G2、G3中PTEN阳性表达率分别为：66.7%、21.7%、18.2%,三组间差别有统计学意义(P<0.05)；PTEN蛋白的表达水平在不同的年龄、病理类型中差异无显著性(P>0.05)。
3.在卵巢癌组织中,EZH2和PTEN蛋白表达存在负相关(rs=-0.425,P=0.001)。
结论：1.EZH2蛋白在卵巢癌组织中高表达,且与临床期别晚、肿瘤分化差及有淋巴结转移密切相关,说明EZH2蛋白可能参与卵巢癌的发生、发展,同时预示该蛋白可能与卵巢癌侵袭转移有关。
2.PTEN蛋白在卵巢癌组织中低表达,且与临床期别晚、肿瘤分化差及有淋巴结转移也相关,提示PTEN蛋白的缺失可能与卵巢癌的发生、发展有关,同时说明PTEN蛋白具有抑制卵巢癌肿瘤细胞侵袭转移的作用。
3.EZH2和PTEN蛋白的表达呈显著负相关,推测PTEN可能通过对EZH2的抑制作用共同参与卵巢癌的发生发展,联合检测对于评价卵巢癌的恶性程度及转移更具有临床价值。
Objective:To investigate the expression of EZH2 and PTEN protein in ovarian tumor tissue, and to explore the relations to clinicopathologic characters of ovarian carcinoma and the relationship of themselves
Methods:Ovarian cancer tissue microarray(OV1005) which was Choosed from chaoying biotechnology company, containing normal oarian tissue 20 cases, benign ovarian tumor 18 cases, border ovarian tumor 7 cases, ovarian carcinoma 55 cases. Then, to detect the expression of EZH2 and PTEN protein by immunohistochemical SP method. The correlations of EZH2 and PTEN with clinicopathological characters were analyzed by X2 test or Fisher'S exact test; their relationship by Spearman.
Results:1. The expression of EZH2 in normal ovarian tissue、benign、border ovarian tumor and ovarian carcinoma Was 5%、33.3%、42.9%、67.3% respectively, and the difference was significant among the four groups(P<0.05).In ovarian carcinoma group, the positive expression of EZH2 in gradeⅠ-Ⅱ(56.7%) Was significantly lower than stageⅢ-Ⅳ(88.9%), the positive expression of EZH2 in no lymph node metastasis group (56.8%) significantly lower than lymph node metastasis (100%), and the differences were both significant (P<0.05). The expression level of EZH2 increased progressively from G1 (42.9%) and G2 (78.3%) to G3 (90.9%), and the difference was significant among the three groups(P<0.05).But no correlation was found between the expression of EZH2 and histological subtype (P>0.05).
2.The expression of PTEN in normal ovarian tissue、benign border ovarian tumor and ovarian carcinoma Was 100%、66.7%、42.9%、38.2% respectively, and the difference was significant among the four groups(P<0.05).In ovarian carcinoma group, the positive expression of EZH2 in gradeⅠ-Ⅱ(51.4%) Was significantly lower than stageⅢ-Ⅳ(11.1%), the positive expression of EZH2 in no lymph node metastasis group (51.4%) significantly lower than lymph node metastasis (0%), and the differences were both significant (P<0.05). The expression level of EZH2 increased progressively from G1 (66.7%) and G2 (21.7%) to G3 (18.2%), and the difference was significant among the three groups(P<0.05).But no correlation was found between the expression of EZH2 and histological subtype (P>0.05).
3. In ovarian carcinoma group, the expression of EZH2 and PTEN shows the negative correlation. (rs=-0.425, P=0.001).
Conclusions:1.The high expression of EZH2 in ovarian cancer has positive correlation with clincal stages、histological grades and lymphaden diversion, indicating that EZH2 protein may be involved in the occurrence of ovarian cancer development, and also indicating that the protein may be associated with invasion and metastasis of ovarian cancer The detection of the protein can be estimated the prognosis of ovarian cancer.
2.The low expression of PTEN in ovarian cancer has positive correlation with clincal stages、histological grades and lymphaden diversion,suggesting that the absence of PTEN protein may be associated with ovarian cancer occurrence and development, at the same time indicating that PTEN protein inhibits the invasion and metastasis of ovarian tumor cells。To detect the protein can understand the prognosis of ovarian cancer.
3.EZH2 was significantly negative correlation with PTEN, suggesting that the two proteins plays an antagonistic role in the development in ovarian cancer.To detect these molecules simultan-eously, which will be more clinical value for the evaluation of mali-gnant、metastasis and prognosis of ovarian cancer.
方法：选用(陕西)超英生物科技公司的卵巢肿瘤组织芯片(OV1005),包括正常卵巢组织20例、上皮性良性卵巢肿瘤18例、上皮性交界性卵巢肿瘤7例、上皮性卵巢癌55例。采用免疫组化方法检测EZH2和PTEN蛋白在卵巢肿瘤组织芯片中的表达。采用X2检验和Fisher确切概率法分析EZH2和PTEN蛋白在各卵巢肿瘤组织中的表达及与临床病理因素之间的关系；用Spearman等级相关分析两种蛋白的相关性。
结果：1.EZH2蛋白在正常卵巢组织、良性卵巢肿瘤、交界性卵巢肿瘤及卵巢癌组织中的表达率分别为5%、33.3%、42.9%、67.3%,四组间差别有统计学意义(P<0.05)。在卵巢癌组织中, EZH2在Ⅰ-Ⅱ期中的表达(56.7%)低于Ⅲ-Ⅳ期中的表达(88.9%),在无淋巴结无转移组中的表达(56.8%)低于有转移组中的表达(100%),两组间差别均有统计学意义(P<0.05)；随病理分级的升高,EZH2蛋白表达水平也增高,G1、G2、G3中EZH2阳性表达率分别为：42.9%、78.3%、90.9%,三组间差别有统计学意义(P<0.05)；EZH2蛋白的表达水平在不同的年龄、病理类型中差异无显著性(P>0.05)；
2.PTEN在正常卵巢组织、良性卵巢肿瘤、交界性卵巢肿瘤及卵巢癌组织中的表达率分别为100%、66.7%、42.9%、38.2%,四组间差别有统计学意义(P<0.05)。在卵巢癌组织中,PTEN在Ⅰ-Ⅱ期中的表达(51.4%)高于Ⅲ-Ⅳ期中的表达(11.1%),在无淋巴结转移组中的表达(51.4%)高于有淋巴结转移组中的表达(0%),两组间差别均有统计学意义(P<0.05)；随病理分级的升高,PTEN表达水平降低,G1、G2、G3中PTEN阳性表达率分别为：66.7%、21.7%、18.2%,三组间差别有统计学意义(P<0.05)；PTEN蛋白的表达水平在不同的年龄、病理类型中差异无显著性(P>0.05)。
3.在卵巢癌组织中,EZH2和PTEN蛋白表达存在负相关(rs=-0.425,P=0.001)。
结论：1.EZH2蛋白在卵巢癌组织中高表达,且与临床期别晚、肿瘤分化差及有淋巴结转移密切相关,说明EZH2蛋白可能参与卵巢癌的发生、发展,同时预示该蛋白可能与卵巢癌侵袭转移有关。
2.PTEN蛋白在卵巢癌组织中低表达,且与临床期别晚、肿瘤分化差及有淋巴结转移也相关,提示PTEN蛋白的缺失可能与卵巢癌的发生、发展有关,同时说明PTEN蛋白具有抑制卵巢癌肿瘤细胞侵袭转移的作用。
3.EZH2和PTEN蛋白的表达呈显著负相关,推测PTEN可能通过对EZH2的抑制作用共同参与卵巢癌的发生发展,联合检测对于评价卵巢癌的恶性程度及转移更具有临床价值。
Objective:To investigate the expression of EZH2 and PTEN protein in ovarian tumor tissue, and to explore the relations to clinicopathologic characters of ovarian carcinoma and the relationship of themselves
Methods:Ovarian cancer tissue microarray(OV1005) which was Choosed from chaoying biotechnology company, containing normal oarian tissue 20 cases, benign ovarian tumor 18 cases, border ovarian tumor 7 cases, ovarian carcinoma 55 cases. Then, to detect the expression of EZH2 and PTEN protein by immunohistochemical SP method. The correlations of EZH2 and PTEN with clinicopathological characters were analyzed by X2 test or Fisher'S exact test; their relationship by Spearman.
Results:1. The expression of EZH2 in normal ovarian tissue、benign、border ovarian tumor and ovarian carcinoma Was 5%、33.3%、42.9%、67.3% respectively, and the difference was significant among the four groups(P<0.05).In ovarian carcinoma group, the positive expression of EZH2 in gradeⅠ-Ⅱ(56.7%) Was significantly lower than stageⅢ-Ⅳ(88.9%), the positive expression of EZH2 in no lymph node metastasis group (56.8%) significantly lower than lymph node metastasis (100%), and the differences were both significant (P<0.05). The expression level of EZH2 increased progressively from G1 (42.9%) and G2 (78.3%) to G3 (90.9%), and the difference was significant among the three groups(P<0.05).But no correlation was found between the expression of EZH2 and histological subtype (P>0.05).
2.The expression of PTEN in normal ovarian tissue、benign border ovarian tumor and ovarian carcinoma Was 100%、66.7%、42.9%、38.2% respectively, and the difference was significant among the four groups(P<0.05).In ovarian carcinoma group, the positive expression of EZH2 in gradeⅠ-Ⅱ(51.4%) Was significantly lower than stageⅢ-Ⅳ(11.1%), the positive expression of EZH2 in no lymph node metastasis group (51.4%) significantly lower than lymph node metastasis (0%), and the differences were both significant (P<0.05). The expression level of EZH2 increased progressively from G1 (66.7%) and G2 (21.7%) to G3 (18.2%), and the difference was significant among the three groups(P<0.05).But no correlation was found between the expression of EZH2 and histological subtype (P>0.05).
3. In ovarian carcinoma group, the expression of EZH2 and PTEN shows the negative correlation. (rs=-0.425, P=0.001).
Conclusions:1.The high expression of EZH2 in ovarian cancer has positive correlation with clincal stages、histological grades and lymphaden diversion, indicating that EZH2 protein may be involved in the occurrence of ovarian cancer development, and also indicating that the protein may be associated with invasion and metastasis of ovarian cancer The detection of the protein can be estimated the prognosis of ovarian cancer.
2.The low expression of PTEN in ovarian cancer has positive correlation with clincal stages、histological grades and lymphaden diversion,suggesting that the absence of PTEN protein may be associated with ovarian cancer occurrence and development, at the same time indicating that PTEN protein inhibits the invasion and metastasis of ovarian tumor cells。To detect the protein can understand the prognosis of ovarian cancer.
3.EZH2 was significantly negative correlation with PTEN, suggesting that the two proteins plays an antagonistic role in the development in ovarian cancer.To detect these molecules simultan-eously, which will be more clinical value for the evaluation of mali-gnant、metastasis and prognosis of ovarian cancer.
引文
[1]Martin VR. Ovarian cancer:an overview of treatment options[J]. Clin J Oncol Nurs,2007,11(2):201-207.
[2]Karanikolas B D, Figueiredo M 1, Wu I. Polycomb group pro-tein enhancer of zeste homolog 2 is an oneogene that promotes the neoplastic transformation of a benign prostatic epithelialcell line[J]. Mol Cancer Res, 2009,7(9):1456-1465.
[3]Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer [J]. EMBO,2003,22 (20):5323-5335.
[4]Carnero A, Blanco-Aparleio C, Benner O,et al. The PTEN/P13K/AKT signalling pathway in cancer, therapeutic implications[J].Curr Cancer Drug Targets,2008,8(3):187-198.
[5]Emanueli C, Sails MB, Pinna A, et al. Prevention of diabetesinduced microangiopathy by human tissue kallikrein gene transfer [J]. Circulation, 2002,10(6):993-999.
[6]Leslie NR, Downess CP.PTEN function:how normal cell control it and tumour cell lose it [J].Biochem J,2004,38(2):1-11.
[7]Hvoeijmarkers JH.Genome maintenance mechanisms of preventing cancer [J].Nature,2001,411(6835):366-374.
[8]Steck PA, et al. Identif ication of a candidate tumour suppressor gene, MMAC 1, at chromosome 10q23.3 that is mutated in multiple advanced cancers[J].Nat Genet,1997,15(4):356-362.
[9]BessonA, Robbins SM, et al. PTEN/MMAC 1/TEP1 in signal trans-duction and tumorigenes [J]. Eur J B iochem,1999,263(3):605.
[10]GiriD, It tm annM. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinom a[J]. H um Patho.l 1999,30(4):419-424.
[11]Emanueli C, Sails MB, Pinna A, et al. Prevention of diabetesinduced microangiopathy by human tissue kallikrein gene transfer [J]. Circulation, 2002,10(6):993-999.
[12]Magklara A, Mellati AA, Wasney GA. ct al. Characterization of the enzymatic activity of human kallikrein 6:Autoaetivation, substrate specificity, and regulation by inhibitors[J]. Biochem Biophys Res Commun,2003,30(7):948-955.
[13]Zheng M, simon R, Kononen J, Sauter G, Mihatsch MJ, Moch H. AnalySis of gene expression Profiles among 3 epithelial oVarian tumor subtypes using cDNA and tissue microarrays. Ai Zheng,2004; 23:771-776.
[14]Andersen CL, Monni O, Wagner U, Kononen J, Barlund M, Bucher C, Haas P, Nocito A, Bissig H, Sauter G, Kallioniemi A. High—throughput copy number analvsis of 17q23 in 3520 tissue specimens by fluorescence in situ hybridization to tissue microarravs. Am J Pathol,2002; 161:73-79.
[15]Li H, Sun Y, Kong QY, Zhang KI, Wang XW, Chen XY, Wang Q Liu J. Combination of nucleic acid and protein isolation with tissue array construction:using defined histologic regions in single frozen tissue blocks for multiple research purposes. Int J Mol Med 2003; 12:299-304.
[16]宋力,崔小健,苏大军,等.EZH2和PTEN基因在前列腺癌组织中的表达及其相关性[J].第四军医大学学报,2006,27(11)：994-996.
[17]李海波,王禾,武国军,等.EZH2和PTEN蛋白联合检测与肾透明细胞癌的相关性研究[J].山西医科大学学报,2009,40(3)：199-201.
[18]JenuweinT, Laible G, Dorn R,R euter G. SET domain proteins modulate chromat in domains in eu-and heterochromatin. Cell Mol Life Sci 1998;54(1):80-93.
[19]Tie F, Prasad-Sinha J, BirveA, et al. A 1-Megadahon ESC/E(z)complex from Drosophila that contains Polycomblike and RPD3[J]. M C B,4.2003, 23:3352.
[20]Julie L, Guy S. Polycomh group genes as epigenetic regulators of normal and leukemic hemopoiesis[J]. Exp Hematol,2003,3:567.
[21]Jacobs J J L, vanLohuizen M. Polycomb repression:from cellular prolifeation and caneer[J]. Biochim Biophys Acta,2002,1602:151.
[22]Cao Ru, Wang L J, Wang H B, et al. Role of histone H3 lysine 27 methylation inpolycomb—group silencing[J]. Science,2002,298:1039.
[23]Plath Kathrin, Fang J, Mlynarczyk-Evans S K, et al. Role of histone H3 lysine 27 methylation in X inactivation[J]. Science,2003,300:131.
[24]Fujii S, Ito K, Ito Y, et al. Enhancer of zeste homologue2(EZH2) down-regulates RUNX3 by increasing histone H3 melhylation[J]. J Biol Chem,2008.283(25):17324-32.
[25]Bryant R J, Winder S J, Cross S S, et al. The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cell [J]. Prostate, 2008,68(3):255-63.
[26]Fujii S, Ochiai A. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci,2008, 99(4):738-746.
[27]KIeer CG, Can Q, Varambal]y S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastie transformation of breast epithelial cells. Proc Natl Acad Sci U S A,2003,100(20):11606-11611.
[28]Tang X, Milyavsky M, Shats I, et al.Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene.2004; 23:5759-5769.
[29]胡沙、李智敏、王静,等.EZH2基因沉默逆转卵巢上皮性癌细胞顺铂耐药性的实验研究[J],中华妇产科杂志.2010,45(3):232-234.
[30]Gonzalez ME, Li X, Toy K, et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCAI. Oncogene,2009.28:843-853.
[31]Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyhransferase enhancer of zeste homologue 2. Clin Cancer Res.2008,14(21):6790-6796.
[32]Hinz S, Kempkensteffen C, Christoph F, et al. Expression of the Polycomb group protein EZH2 and its relation to outcome in patients with urethelial carcinoma of the bladder. J Cancer RasCl in Oncol,2008,134:331-336.
[33]龚志斌,厉有名,虞朝辉.EZH2在肝细胞性肝癌中的表达及其对HepG2增殖作用的研究.实用肿瘤杂志,2006,21(6):523-526.
[34]Matsukawa Y, Semba S, Kato H, et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci,2006,97(6):484-491.
[35]Tolini T, Bagella L, Dandrilli G, et al. EZH2 reduces the ability Of HDAC1-dependent pRb2/p130 transcriptional of CyclinA. Oncogene, 2004,23(28):4930-4937.
[36]Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419(6907):624-629.
[37]Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005; 280:22437-22444.
[38]Bachmann IM, Halvorsen OJ, ColIett K, et al. EZH2 expression is associated with high prelfferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol,2006,24(2):268-273.
[39]Mimori K, Ogawa K, Okamote M, et al. Clinical siguifieanco of enhancer of zeste homolog 2 expression in colorectal cancer case8. Eur J Surg Oncol, 2005,31(4):376-380.
[40]Vtkony H, Raaphont FM, Otte AP, et al. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. J Clin Pathol,2008,61(6):744-749.
[41]Yang L, Kuang L G, Zheng HC, et al. PTEN encoding product:a marker for tumorigenesis and progression of gastric carcinoma[J]. World J Gastroenterol, 2003,9(1):35-39.
[42]Vazques F, Matsuoka S, Sellersw WR, et al. Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane[J]. Proc Natl Acad Sci USA,2006,103(10):3633-3638.
[43]Weng L P, Smith W M, Brow n J L, et al. PTEN w ith inhibits Insulin-stimulated M EK/MARK activation and cell grow th by blocking IRSH phosphorylation and IRS21/Grb22/Sos complex formation in a breastmodel[J]. Hum M ol Genet,2001,10 (6):605-616.
[44]Raftopoulou M, EtienneM anneville S, Self A, et al. Regulation of cellm igration by the C2 dom ain of the turn or suppressor PTEN[J].Science,2004, 303(5661):1179.
[45]Sasal I, Sellers WR. The biolony and clinical relevance of tile PTEN tumor suppressor pathways[J].J Clin Oncol,2004,22(14):2954-2963.
[46]Huang J, Kotons CD. PTEN modulates vascular endothelial growth factormediated signaling and angiogenic effects [J]. B iol Chem,2002,277 (13):10760-10766.
[47]Wu R, Hendrix-Lucas N, Kuick R, et al.Mouse Model of Human ovarian Endomet rioid Adenocarcinoma Based on Somatic Defects in the Wnt/ beta-Catenin and PI 3 K/Pten Signaling Pathway [J]. Cancer Cell,2007, 11(4):321-333.
[48]Pandey SK, He HJ, Chesley A, et al. Wortmannln-sensitive pathway is required for in sulinstimulated phosphorylation of inhibitor kappaBalpha[J]. Ednocrinol-ogy,2002,143(2):375-385.
[49]Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequentln endometrial carcinoma but rare in other common gynecologica Malignancies.Cancer Res,1997,57:3935-3940.
[50]陈颖,李建军,杨雪飞,等PTEN蛋白在卵巢癌发生发展过程中的表达及临床病理意.中国医科大学学报,2004,33:156-158.
[51]杨震,孙国平.抑癌基因PTEN与原发性肝癌的研究进展[J].安徽医药,2006,10(2)：85-87.
[52]Cheong JW,Eom JI, Maeng HY,et al. Phosphatase and tensin homologue phosphorylation in the C—terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome[J]. Br J HaematOl.2003,122:454-456.
[53]Schondorf T, Cohring UJ, RothG. Time to progression is dependent on the expression of the tumour suppressor PTEN in ovarian cancer patients[J]. Euro Jo-urnal of Cli Inv,2003,33(1):256-260.
[54]Di CA, Pandolfi PP. The multiple roles of PTEN in tumor suppression[J]. Cell,2000,100 (4):387-390.
[55]Yang L, Kuang LG, Zheng HC, et al. PTEN encoding product:a marker for tumorigenesis and progression of gastric carinoma[J].World J Gastroenterol,2003.9(1):35-39.
[1]JacobsJ J,vanL ohuizen M.Polycombr epression:from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 2002;1602(2):151-61.
[2]Gil J, Bernard D, Peters G. Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol,2005,24(2):117.125.
[3]Plath K, Fang J, Mlynarczyk-Evans SK, et al. Role of histone H3 lysine 27 methylation in X inactivation. Science,2003,300(5616):131—135.
[4]Franeis NJ Kingston R E.mechanisms of transcriptional memory. Nature reviews2001;2:409-421.
[5]Gonzalez ME, Li X, Toy K, et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCAI. Oncogene,2009.28:843-853.
[6]Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyhransferase enhancer of zeste homologue 2. Clin Cancer Res.2008,14(21):6790-6796.
[7]Fujii S, Ochiai A. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci,2008, 99(4):738-746.
[8]Hinz S, Kempkensteffen C, Christoph F, et al. Expression of the Polycomb group protein EZH2 and its relation to outcome in patients with urethelial carcinoma of the bladder. J Cancer RasCl in Oncol,2008,134:331-336.
[9]龚志斌,厉有名,虞朝辉.EZH2在肝细胞性肝癌中的表达及其对HepG2增殖作用的研究.实用肿瘤杂志,2006,21(6):523-526.
[10]Carnero A, Blanco-Aparleio C, Benner O,et al. The PTEN/P13K/AKT signalling pathway in cancer, therapeutic implications[J].Curr Cancer Drug Targets,2008,8(3):187-198.
[11]Karanikolas B D, Figueiredo M 1, Wu I. Polycomb group pro-tein enhancer of zeste homolog 2 is an oneogene that promotes the neoplastic transformation of a benign prostatic epithelialcell line[J]. Mol Cancer Res, 2009,7(9):1456-1465.
[12]Abel KJ,Brody LC, Valdes JM,ErdosMR,McKinleyDR,C astilla LH, etal.Characterization of EZH1, a human homolog of Drosophi la Enhancer of zeste near BRCA1. Genomics 1996;37(2):161-71.
[13]Hobert O,Jallal B,Ullrich A.Interaction of Vav with ENX-l,a putative transcriptional regulator of homeobox gene expression. Mol Cell Biol 1996;16(6):3066-73.
[14]Chen H, Rossier C, Antonorakis S E. Cloning of a human homolog of the Drosophila enhancer of zeste gene(EZH2)that maps to chromosome 21q22.2[J].Genomics,1996,38:30-37.
[15]Carlos Cardoso, Cecile Mignon, Gilles Hetet, etal. The human EZH2 gene: genomic organisatin and revised mapping in 7q35 within the critical region formalignantmyeloiddisorders[J]. Eur J Hum Genetics,2000, (3):174-180.
[16]Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH Wagner-MePherson C, etal. The DNA sequence of humane hromosome 7.Nature 2003:424(6945):157-64.
[17]JenuweinT, Laible G, Dorn R,R euter G. SET domain proteins modulate chromat in domains in eu-and heterochromatin. Cell Mol Life Sci 1998;54(1):80-93.
[18]Satijn D P, Otte A P. Polycomb group protein complexes:do different complexes regulate distinct target genes[J]. Bioehim Biophys Acta,1999, 1447:1.
[19]Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer [J]. EMBO,2003,22 (20):5323-5335.
[20]Kuzmichev A, Jenuwein T, Tempst P, et al. Different EZH2-containing complexes target methylation of histoneHl nucleosomal histene H3. Mol Cell,2004,14(2):183-193.
[21]Kleer CG, Can Q, Varambal]y S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastie transformation of breast epithelial cells. Proc Natl Acad Sci U S A,2003,100(20):11606-11611.
[22]Tolini T, Bagella L, Dandrilli G, et al. EZH2 reduces the ability Of HDAC1-dependent pRb2/p130 transcriptional of CyclinA. Oncogene, 2004,23(28):4930-4937.
[23]Tang X, Milyavsky M, Shats 1, et al. Activated p53 suppresses the histone methyltransferase EzH2 gene[J]. Oncogene,2004,23(34):5759—69.
[24]VarambaUy S, Dhanasekaran SM, Zhou M. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature,2002, 419(6907):624-629.
[25]Chen H, Tu SW, Hsieh JI'. Dowll-reguhtion of human DAB2IP gene expression mediated by polycornb EZH2 complex and histone deacetylase in prostate cancer.J Biol Chem,2005,280(23):22437-22444.
[26]Beke L,Nuytten M, Van Eynde A,et.al.The gene encoding the prastatic tumor suppressor PSP94 is a target for re Polycomb group pression by the Polycomb group protein EZH2. Oncogene,2007,26(31):4590-4595.
[27]李道旺、吴强、马成民、王红群,等.EZH2蛋白在前列腺癌中的表达[J].安徽医科大学学报,2010,45(4)：562-564.
[28]Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol,2006,24:268—73.
[29]Bryant R J, Cross N A, Eaton C L, et al. EzH2 promotes Proliferation and invasiveness of prostate cancer cells[J]. Prostate,2007,67(5):547—56.
[30]Bryant R J, Winder S J, Cross S S, et al. The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cell [J]. Prostate, 2008,68(3):255-63.
[31]Chen H. Tu SW, Hsiehj T, et al. Down-regulation of human DAB2IP gene Expression mediated by polycomb EZH2 complexl and histone deaceetylase in prostate cancer[J].Biol Chem,2005,280(23): 22437—22444.
[32]Gata R, Matsueda S, Yao A, et al. Identification of polycomb group protein enhancer of seste homolog 2(EZH2)—derived peptides immunogenic in HLA-A24+prostate cancer patients. Prostate,2004,60(4):273-281.
[33]Itoh Y, Komohara Y, Komatsu N, et al. New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic Tlymphocytes in human leukoyte antigen-A2+prostate cancer patients.Oncol Rep,2007,18(5):1231-1237.
[34]唐移忠、田金华,曾定元.组蛋白甲基化转移酶EZH2在卵巢癌组织中的表达及意义[J].现代预防医学.2009,36(10)：1980-2.
[35]Lu C, Bonome T, Li Y, et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res,2007,67(4):1757-1768.
[36]胡沙、李智敏、王静,等.EZH2基因沉默逆转卵巢上皮性癌细胞顺铂耐药性的实验研究[J],中华妇产志.2010,45(3):232-234.
[37]Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high prelfferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol,2006,24(2):268-273.
[38]李全香,刘君,王志芳,等.EZH2在子宫内膜癌中表达的意义[J].中国妇幼保健,2009,24(10)：1403-6.
[39]Rajasekhar Vk, Beqemamann M. Concise Review:Role of polycomb Group Proteins in Development and Disease:A Stem Cell Perspective[J]. Stem Cells,2007,25(10):2498—2510.
[40]Matsukawa Y, Semba S, Kato H, et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci,2006,97(6):484-491.
[41]蔡干慧,王珂,等.PcG蛋白EZH2在胃癌发生发展过程中的表达及其临床意义[J].胃肠病学,2010,15(6):339-342.
[42]苗芳,李劲松.EZH2和Ki-67在胃癌中的表达及其临床意义.泰山医学院学报,2008,29(2)：87-89.
[43]Mattioli E, Vogiatzi P, Sun A, et al. Immuno-histochemical analysis of pRb2/p130,VEGF,EZH2,p53,p16(INK4A),p27(KIPl),p21(WAF),Ki-67 expmssion patterns in gastric cancer.[J],2007,210(1):183-191.
[44]Fujii S, Ochiai A. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci,2008, 99(4):738-746.
[45]Fujii S, Ito K, Ito Y, et al. Enhancer of zeste homologue2(EZH2) down-regulates RUNX3 by increasing histone H3 melhylation[J]. J Biol Chem,2008.283(25):17324-32.
[46]Raaphorst FM, Meijer CJ, Fieret E, et al. Pcody differentiated breast carcinoma is associated with increased expression of the human polycomb group EzH2 gene. Neoplasia,2003,5(6):481-488.
[47]Collett K,EideG E,A rnesJ,S tefanssonT M,F ideJ,B raatenA, et al.Expression of Enhancer of Zeste Homologue 2 is Significantly Associated with Increased Tumor Cell Proliferation and Is a Marker of Aggressive Breast Cancer.Clin Cancer Res 2006; 12(4):1168-1174.
[48]董桂兰,等.EZH2和P53在乳腺癌中的表达及相关性探讨.中国肿瘤临床,2007,34(16):931-933.
[49]Ding L, Erdmann C, Chinnaiyan, et al. Identification of EZH2 is a molecular marker for a precancerous state in morphologically normal breast tissues.Cancer Res,2006,66(8):4095-4099.
[50]康凯夫,王晓蔚,陈小伍,等.Bm i21和EZH2在肝癌中的表达及其临床意义.临床与实验病理学杂志,2008,24(6):743-744.
[51]龚志斌,厉有名,虞朝辉.EZH2在肝细胞性肝癌中的表达及其对HepG2增殖作用的研究.实用肿瘤杂志,2006,21(6):523-526.
[52]Sudo T, UtsuIlomiya T, Mimori K, et al. Clinicopatllological significance Of EZH2 mRNA expression patients with hepatocellular carcinoma. BrJ Cancer,2005,92(9):1754-1758.
[53]Anzola M.Hepatocellular carcinoma:role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis[J]. J Viral Hepatitis,2004,11(5): 383-393.
[54]Chen Y,Lin MC,Yao H.et al. Lentivirus-mediated RNA interference targeting enhancer of zegte homolog 2 inhibits hepatoeellular carcinoma growth through down-regulation ofstathmin. Hepatelogy,2007,46(1): 200-208.
[55]Van Kemenade FJ, Raaphorst FM, Blokzijl T, et al. Coexpression of BMI-1 and EZH2 polyeomb—group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood,2001, 97(12):3896-3901.
[56]Dukers DF, vanGalen JC, Giroth C, Jansen P,Sewalt RG, ORe AP, et al. Unique polyeomb gene expression pattern in Hodgkin'S lymphoma and Hodgkin'S lym-phoma-derived cell lines. AmJ Pathol 2004:164(3): 873—81.
[57]Su IH, Basavaraj A, Krutchinsky AN, Hobert O, Ullrich A, Chait BT, et al. EZh2 controls B cell development through histoneH3 methylation and Igh rearrangement. Nat Immunol 2003;4(2):124-31.
[58]Ranphorst FM, van Kemenade FJ, Blokzijl T, et al. Coexpression of BMI-1 and EZH2 polyeomb group genes in Reed-Sternberg cells of Hedgkin's disease. Am J Pathol,2000,157(3):709-715.
[59]OUGOLKOV A, BILIM V N, BILLADEAU D D. Regulation of pancreatic tumor ceil proliferation and ehemoresistance by the histone methyltransferase enhancer of zeste homologue 2[J]. Clin Cancer Res,2008,14(21): 6790-6796.
[60]MemIa E, MattioIi E, Minimo C, et al. Immunohistochelllical eValuation ofpRb2/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett esophagus. J Cell Physiol,2006,207(2):512-519.
[61]Richter GH, Plehm S, Fesan A, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ecuxtermal differentiation[J]. Proc Nell Acad Sci USA,2009.106(13): 5324-5329.
[62]Burdaeh S, Plehm S, Unland R, et al. Epigenetic maintenance of sternness and malignancy in peripheral neuroectodermal tumors by EZH2[J]. Cell Cycle,2009,8(13):1991-1996.
[63]Ciarapica R, Rnsso G, VergineiliF, et al. Deregulated expression of miR-26a and Ezh2in Rhmbdomyosarcoma[J]. Cell Cycle,2009,8(1):172-175
[2]Karanikolas B D, Figueiredo M 1, Wu I. Polycomb group pro-tein enhancer of zeste homolog 2 is an oneogene that promotes the neoplastic transformation of a benign prostatic epithelialcell line[J]. Mol Cancer Res, 2009,7(9):1456-1465.
[3]Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer [J]. EMBO,2003,22 (20):5323-5335.
[4]Carnero A, Blanco-Aparleio C, Benner O,et al. The PTEN/P13K/AKT signalling pathway in cancer, therapeutic implications[J].Curr Cancer Drug Targets,2008,8(3):187-198.
[5]Emanueli C, Sails MB, Pinna A, et al. Prevention of diabetesinduced microangiopathy by human tissue kallikrein gene transfer [J]. Circulation, 2002,10(6):993-999.
[6]Leslie NR, Downess CP.PTEN function:how normal cell control it and tumour cell lose it [J].Biochem J,2004,38(2):1-11.
[7]Hvoeijmarkers JH.Genome maintenance mechanisms of preventing cancer [J].Nature,2001,411(6835):366-374.
[8]Steck PA, et al. Identif ication of a candidate tumour suppressor gene, MMAC 1, at chromosome 10q23.3 that is mutated in multiple advanced cancers[J].Nat Genet,1997,15(4):356-362.
[9]BessonA, Robbins SM, et al. PTEN/MMAC 1/TEP1 in signal trans-duction and tumorigenes [J]. Eur J B iochem,1999,263(3):605.
[10]GiriD, It tm annM. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinom a[J]. H um Patho.l 1999,30(4):419-424.
[11]Emanueli C, Sails MB, Pinna A, et al. Prevention of diabetesinduced microangiopathy by human tissue kallikrein gene transfer [J]. Circulation, 2002,10(6):993-999.
[12]Magklara A, Mellati AA, Wasney GA. ct al. Characterization of the enzymatic activity of human kallikrein 6:Autoaetivation, substrate specificity, and regulation by inhibitors[J]. Biochem Biophys Res Commun,2003,30(7):948-955.
[13]Zheng M, simon R, Kononen J, Sauter G, Mihatsch MJ, Moch H. AnalySis of gene expression Profiles among 3 epithelial oVarian tumor subtypes using cDNA and tissue microarrays. Ai Zheng,2004; 23:771-776.
[14]Andersen CL, Monni O, Wagner U, Kononen J, Barlund M, Bucher C, Haas P, Nocito A, Bissig H, Sauter G, Kallioniemi A. High—throughput copy number analvsis of 17q23 in 3520 tissue specimens by fluorescence in situ hybridization to tissue microarravs. Am J Pathol,2002; 161:73-79.
[15]Li H, Sun Y, Kong QY, Zhang KI, Wang XW, Chen XY, Wang Q Liu J. Combination of nucleic acid and protein isolation with tissue array construction:using defined histologic regions in single frozen tissue blocks for multiple research purposes. Int J Mol Med 2003; 12:299-304.
[16]宋力,崔小健,苏大军,等.EZH2和PTEN基因在前列腺癌组织中的表达及其相关性[J].第四军医大学学报,2006,27(11)：994-996.
[17]李海波,王禾,武国军,等.EZH2和PTEN蛋白联合检测与肾透明细胞癌的相关性研究[J].山西医科大学学报,2009,40(3)：199-201.
[18]JenuweinT, Laible G, Dorn R,R euter G. SET domain proteins modulate chromat in domains in eu-and heterochromatin. Cell Mol Life Sci 1998;54(1):80-93.
[19]Tie F, Prasad-Sinha J, BirveA, et al. A 1-Megadahon ESC/E(z)complex from Drosophila that contains Polycomblike and RPD3[J]. M C B,4.2003, 23:3352.
[20]Julie L, Guy S. Polycomh group genes as epigenetic regulators of normal and leukemic hemopoiesis[J]. Exp Hematol,2003,3:567.
[21]Jacobs J J L, vanLohuizen M. Polycomb repression:from cellular prolifeation and caneer[J]. Biochim Biophys Acta,2002,1602:151.
[22]Cao Ru, Wang L J, Wang H B, et al. Role of histone H3 lysine 27 methylation inpolycomb—group silencing[J]. Science,2002,298:1039.
[23]Plath Kathrin, Fang J, Mlynarczyk-Evans S K, et al. Role of histone H3 lysine 27 methylation in X inactivation[J]. Science,2003,300:131.
[24]Fujii S, Ito K, Ito Y, et al. Enhancer of zeste homologue2(EZH2) down-regulates RUNX3 by increasing histone H3 melhylation[J]. J Biol Chem,2008.283(25):17324-32.
[25]Bryant R J, Winder S J, Cross S S, et al. The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cell [J]. Prostate, 2008,68(3):255-63.
[26]Fujii S, Ochiai A. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci,2008, 99(4):738-746.
[27]KIeer CG, Can Q, Varambal]y S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastie transformation of breast epithelial cells. Proc Natl Acad Sci U S A,2003,100(20):11606-11611.
[28]Tang X, Milyavsky M, Shats I, et al.Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene.2004; 23:5759-5769.
[29]胡沙、李智敏、王静,等.EZH2基因沉默逆转卵巢上皮性癌细胞顺铂耐药性的实验研究[J],中华妇产科杂志.2010,45(3):232-234.
[30]Gonzalez ME, Li X, Toy K, et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCAI. Oncogene,2009.28:843-853.
[31]Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyhransferase enhancer of zeste homologue 2. Clin Cancer Res.2008,14(21):6790-6796.
[32]Hinz S, Kempkensteffen C, Christoph F, et al. Expression of the Polycomb group protein EZH2 and its relation to outcome in patients with urethelial carcinoma of the bladder. J Cancer RasCl in Oncol,2008,134:331-336.
[33]龚志斌,厉有名,虞朝辉.EZH2在肝细胞性肝癌中的表达及其对HepG2增殖作用的研究.实用肿瘤杂志,2006,21(6):523-526.
[34]Matsukawa Y, Semba S, Kato H, et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci,2006,97(6):484-491.
[35]Tolini T, Bagella L, Dandrilli G, et al. EZH2 reduces the ability Of HDAC1-dependent pRb2/p130 transcriptional of CyclinA. Oncogene, 2004,23(28):4930-4937.
[36]Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419(6907):624-629.
[37]Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005; 280:22437-22444.
[38]Bachmann IM, Halvorsen OJ, ColIett K, et al. EZH2 expression is associated with high prelfferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol,2006,24(2):268-273.
[39]Mimori K, Ogawa K, Okamote M, et al. Clinical siguifieanco of enhancer of zeste homolog 2 expression in colorectal cancer case8. Eur J Surg Oncol, 2005,31(4):376-380.
[40]Vtkony H, Raaphont FM, Otte AP, et al. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. J Clin Pathol,2008,61(6):744-749.
[41]Yang L, Kuang L G, Zheng HC, et al. PTEN encoding product:a marker for tumorigenesis and progression of gastric carcinoma[J]. World J Gastroenterol, 2003,9(1):35-39.
[42]Vazques F, Matsuoka S, Sellersw WR, et al. Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane[J]. Proc Natl Acad Sci USA,2006,103(10):3633-3638.
[43]Weng L P, Smith W M, Brow n J L, et al. PTEN w ith inhibits Insulin-stimulated M EK/MARK activation and cell grow th by blocking IRSH phosphorylation and IRS21/Grb22/Sos complex formation in a breastmodel[J]. Hum M ol Genet,2001,10 (6):605-616.
[44]Raftopoulou M, EtienneM anneville S, Self A, et al. Regulation of cellm igration by the C2 dom ain of the turn or suppressor PTEN[J].Science,2004, 303(5661):1179.
[45]Sasal I, Sellers WR. The biolony and clinical relevance of tile PTEN tumor suppressor pathways[J].J Clin Oncol,2004,22(14):2954-2963.
[46]Huang J, Kotons CD. PTEN modulates vascular endothelial growth factormediated signaling and angiogenic effects [J]. B iol Chem,2002,277 (13):10760-10766.
[47]Wu R, Hendrix-Lucas N, Kuick R, et al.Mouse Model of Human ovarian Endomet rioid Adenocarcinoma Based on Somatic Defects in the Wnt/ beta-Catenin and PI 3 K/Pten Signaling Pathway [J]. Cancer Cell,2007, 11(4):321-333.
[48]Pandey SK, He HJ, Chesley A, et al. Wortmannln-sensitive pathway is required for in sulinstimulated phosphorylation of inhibitor kappaBalpha[J]. Ednocrinol-ogy,2002,143(2):375-385.
[49]Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequentln endometrial carcinoma but rare in other common gynecologica Malignancies.Cancer Res,1997,57:3935-3940.
[50]陈颖,李建军,杨雪飞,等PTEN蛋白在卵巢癌发生发展过程中的表达及临床病理意.中国医科大学学报,2004,33:156-158.
[51]杨震,孙国平.抑癌基因PTEN与原发性肝癌的研究进展[J].安徽医药,2006,10(2)：85-87.
[52]Cheong JW,Eom JI, Maeng HY,et al. Phosphatase and tensin homologue phosphorylation in the C—terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome[J]. Br J HaematOl.2003,122:454-456.
[53]Schondorf T, Cohring UJ, RothG. Time to progression is dependent on the expression of the tumour suppressor PTEN in ovarian cancer patients[J]. Euro Jo-urnal of Cli Inv,2003,33(1):256-260.
[54]Di CA, Pandolfi PP. The multiple roles of PTEN in tumor suppression[J]. Cell,2000,100 (4):387-390.
[55]Yang L, Kuang LG, Zheng HC, et al. PTEN encoding product:a marker for tumorigenesis and progression of gastric carinoma[J].World J Gastroenterol,2003.9(1):35-39.
[1]JacobsJ J,vanL ohuizen M.Polycombr epression:from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 2002;1602(2):151-61.
[2]Gil J, Bernard D, Peters G. Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol,2005,24(2):117.125.
[3]Plath K, Fang J, Mlynarczyk-Evans SK, et al. Role of histone H3 lysine 27 methylation in X inactivation. Science,2003,300(5616):131—135.
[4]Franeis NJ Kingston R E.mechanisms of transcriptional memory. Nature reviews2001;2:409-421.
[5]Gonzalez ME, Li X, Toy K, et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCAI. Oncogene,2009.28:843-853.
[6]Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyhransferase enhancer of zeste homologue 2. Clin Cancer Res.2008,14(21):6790-6796.
[7]Fujii S, Ochiai A. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci,2008, 99(4):738-746.
[8]Hinz S, Kempkensteffen C, Christoph F, et al. Expression of the Polycomb group protein EZH2 and its relation to outcome in patients with urethelial carcinoma of the bladder. J Cancer RasCl in Oncol,2008,134:331-336.
[9]龚志斌,厉有名,虞朝辉.EZH2在肝细胞性肝癌中的表达及其对HepG2增殖作用的研究.实用肿瘤杂志,2006,21(6):523-526.
[10]Carnero A, Blanco-Aparleio C, Benner O,et al. The PTEN/P13K/AKT signalling pathway in cancer, therapeutic implications[J].Curr Cancer Drug Targets,2008,8(3):187-198.
[11]Karanikolas B D, Figueiredo M 1, Wu I. Polycomb group pro-tein enhancer of zeste homolog 2 is an oneogene that promotes the neoplastic transformation of a benign prostatic epithelialcell line[J]. Mol Cancer Res, 2009,7(9):1456-1465.
[12]Abel KJ,Brody LC, Valdes JM,ErdosMR,McKinleyDR,C astilla LH, etal.Characterization of EZH1, a human homolog of Drosophi la Enhancer of zeste near BRCA1. Genomics 1996;37(2):161-71.
[13]Hobert O,Jallal B,Ullrich A.Interaction of Vav with ENX-l,a putative transcriptional regulator of homeobox gene expression. Mol Cell Biol 1996;16(6):3066-73.
[14]Chen H, Rossier C, Antonorakis S E. Cloning of a human homolog of the Drosophila enhancer of zeste gene(EZH2)that maps to chromosome 21q22.2[J].Genomics,1996,38:30-37.
[15]Carlos Cardoso, Cecile Mignon, Gilles Hetet, etal. The human EZH2 gene: genomic organisatin and revised mapping in 7q35 within the critical region formalignantmyeloiddisorders[J]. Eur J Hum Genetics,2000, (3):174-180.
[16]Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH Wagner-MePherson C, etal. The DNA sequence of humane hromosome 7.Nature 2003:424(6945):157-64.
[17]JenuweinT, Laible G, Dorn R,R euter G. SET domain proteins modulate chromat in domains in eu-and heterochromatin. Cell Mol Life Sci 1998;54(1):80-93.
[18]Satijn D P, Otte A P. Polycomb group protein complexes:do different complexes regulate distinct target genes[J]. Bioehim Biophys Acta,1999, 1447:1.
[19]Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer [J]. EMBO,2003,22 (20):5323-5335.
[20]Kuzmichev A, Jenuwein T, Tempst P, et al. Different EZH2-containing complexes target methylation of histoneHl nucleosomal histene H3. Mol Cell,2004,14(2):183-193.
[21]Kleer CG, Can Q, Varambal]y S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastie transformation of breast epithelial cells. Proc Natl Acad Sci U S A,2003,100(20):11606-11611.
[22]Tolini T, Bagella L, Dandrilli G, et al. EZH2 reduces the ability Of HDAC1-dependent pRb2/p130 transcriptional of CyclinA. Oncogene, 2004,23(28):4930-4937.
[23]Tang X, Milyavsky M, Shats 1, et al. Activated p53 suppresses the histone methyltransferase EzH2 gene[J]. Oncogene,2004,23(34):5759—69.
[24]VarambaUy S, Dhanasekaran SM, Zhou M. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature,2002, 419(6907):624-629.
[25]Chen H, Tu SW, Hsieh JI'. Dowll-reguhtion of human DAB2IP gene expression mediated by polycornb EZH2 complex and histone deacetylase in prostate cancer.J Biol Chem,2005,280(23):22437-22444.
[26]Beke L,Nuytten M, Van Eynde A,et.al.The gene encoding the prastatic tumor suppressor PSP94 is a target for re Polycomb group pression by the Polycomb group protein EZH2. Oncogene,2007,26(31):4590-4595.
[27]李道旺、吴强、马成民、王红群,等.EZH2蛋白在前列腺癌中的表达[J].安徽医科大学学报,2010,45(4)：562-564.
[28]Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol,2006,24:268—73.
[29]Bryant R J, Cross N A, Eaton C L, et al. EzH2 promotes Proliferation and invasiveness of prostate cancer cells[J]. Prostate,2007,67(5):547—56.
[30]Bryant R J, Winder S J, Cross S S, et al. The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cell [J]. Prostate, 2008,68(3):255-63.
[31]Chen H. Tu SW, Hsiehj T, et al. Down-regulation of human DAB2IP gene Expression mediated by polycomb EZH2 complexl and histone deaceetylase in prostate cancer[J].Biol Chem,2005,280(23): 22437—22444.
[32]Gata R, Matsueda S, Yao A, et al. Identification of polycomb group protein enhancer of seste homolog 2(EZH2)—derived peptides immunogenic in HLA-A24+prostate cancer patients. Prostate,2004,60(4):273-281.
[33]Itoh Y, Komohara Y, Komatsu N, et al. New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic Tlymphocytes in human leukoyte antigen-A2+prostate cancer patients.Oncol Rep,2007,18(5):1231-1237.
[34]唐移忠、田金华,曾定元.组蛋白甲基化转移酶EZH2在卵巢癌组织中的表达及意义[J].现代预防医学.2009,36(10)：1980-2.
[35]Lu C, Bonome T, Li Y, et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res,2007,67(4):1757-1768.
[36]胡沙、李智敏、王静,等.EZH2基因沉默逆转卵巢上皮性癌细胞顺铂耐药性的实验研究[J],中华妇产志.2010,45(3):232-234.
[37]Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high prelfferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol,2006,24(2):268-273.
[38]李全香,刘君,王志芳,等.EZH2在子宫内膜癌中表达的意义[J].中国妇幼保健,2009,24(10)：1403-6.
[39]Rajasekhar Vk, Beqemamann M. Concise Review:Role of polycomb Group Proteins in Development and Disease:A Stem Cell Perspective[J]. Stem Cells,2007,25(10):2498—2510.
[40]Matsukawa Y, Semba S, Kato H, et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci,2006,97(6):484-491.
[41]蔡干慧,王珂,等.PcG蛋白EZH2在胃癌发生发展过程中的表达及其临床意义[J].胃肠病学,2010,15(6):339-342.
[42]苗芳,李劲松.EZH2和Ki-67在胃癌中的表达及其临床意义.泰山医学院学报,2008,29(2)：87-89.
[43]Mattioli E, Vogiatzi P, Sun A, et al. Immuno-histochemical analysis of pRb2/p130,VEGF,EZH2,p53,p16(INK4A),p27(KIPl),p21(WAF),Ki-67 expmssion patterns in gastric cancer.[J],2007,210(1):183-191.
[44]Fujii S, Ochiai A. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci,2008, 99(4):738-746.
[45]Fujii S, Ito K, Ito Y, et al. Enhancer of zeste homologue2(EZH2) down-regulates RUNX3 by increasing histone H3 melhylation[J]. J Biol Chem,2008.283(25):17324-32.
[46]Raaphorst FM, Meijer CJ, Fieret E, et al. Pcody differentiated breast carcinoma is associated with increased expression of the human polycomb group EzH2 gene. Neoplasia,2003,5(6):481-488.
[47]Collett K,EideG E,A rnesJ,S tefanssonT M,F ideJ,B raatenA, et al.Expression of Enhancer of Zeste Homologue 2 is Significantly Associated with Increased Tumor Cell Proliferation and Is a Marker of Aggressive Breast Cancer.Clin Cancer Res 2006; 12(4):1168-1174.
[48]董桂兰,等.EZH2和P53在乳腺癌中的表达及相关性探讨.中国肿瘤临床,2007,34(16):931-933.
[49]Ding L, Erdmann C, Chinnaiyan, et al. Identification of EZH2 is a molecular marker for a precancerous state in morphologically normal breast tissues.Cancer Res,2006,66(8):4095-4099.
[50]康凯夫,王晓蔚,陈小伍,等.Bm i21和EZH2在肝癌中的表达及其临床意义.临床与实验病理学杂志,2008,24(6):743-744.
[51]龚志斌,厉有名,虞朝辉.EZH2在肝细胞性肝癌中的表达及其对HepG2增殖作用的研究.实用肿瘤杂志,2006,21(6):523-526.
[52]Sudo T, UtsuIlomiya T, Mimori K, et al. Clinicopatllological significance Of EZH2 mRNA expression patients with hepatocellular carcinoma. BrJ Cancer,2005,92(9):1754-1758.
[53]Anzola M.Hepatocellular carcinoma:role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis[J]. J Viral Hepatitis,2004,11(5): 383-393.
[54]Chen Y,Lin MC,Yao H.et al. Lentivirus-mediated RNA interference targeting enhancer of zegte homolog 2 inhibits hepatoeellular carcinoma growth through down-regulation ofstathmin. Hepatelogy,2007,46(1): 200-208.
[55]Van Kemenade FJ, Raaphorst FM, Blokzijl T, et al. Coexpression of BMI-1 and EZH2 polyeomb—group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood,2001, 97(12):3896-3901.
[56]Dukers DF, vanGalen JC, Giroth C, Jansen P,Sewalt RG, ORe AP, et al. Unique polyeomb gene expression pattern in Hodgkin'S lymphoma and Hodgkin'S lym-phoma-derived cell lines. AmJ Pathol 2004:164(3): 873—81.
[57]Su IH, Basavaraj A, Krutchinsky AN, Hobert O, Ullrich A, Chait BT, et al. EZh2 controls B cell development through histoneH3 methylation and Igh rearrangement. Nat Immunol 2003;4(2):124-31.
[58]Ranphorst FM, van Kemenade FJ, Blokzijl T, et al. Coexpression of BMI-1 and EZH2 polyeomb group genes in Reed-Sternberg cells of Hedgkin's disease. Am J Pathol,2000,157(3):709-715.
[59]OUGOLKOV A, BILIM V N, BILLADEAU D D. Regulation of pancreatic tumor ceil proliferation and ehemoresistance by the histone methyltransferase enhancer of zeste homologue 2[J]. Clin Cancer Res,2008,14(21): 6790-6796.
[60]MemIa E, MattioIi E, Minimo C, et al. Immunohistochelllical eValuation ofpRb2/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett esophagus. J Cell Physiol,2006,207(2):512-519.
[61]Richter GH, Plehm S, Fesan A, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ecuxtermal differentiation[J]. Proc Nell Acad Sci USA,2009.106(13): 5324-5329.
[62]Burdaeh S, Plehm S, Unland R, et al. Epigenetic maintenance of sternness and malignancy in peripheral neuroectodermal tumors by EZH2[J]. Cell Cycle,2009,8(13):1991-1996.
[63]Ciarapica R, Rnsso G, VergineiliF, et al. Deregulated expression of miR-26a and Ezh2in Rhmbdomyosarcoma[J]. Cell Cycle,2009,8(1):172-175